Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.
作者信息
Nesic Ksenija, Rybinski Katherine, Ratnayake Gayanie, Ho Gwo-Yaw, Lim Ratana, Radke Marc, Neagle Chloe, Swisher Elizabeth M, Wakefield Matthew J, Barker Holly E, Furuuchi Keiji, Scott Clare L, Vandenberg Cassandra J
机构信息
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.
出版信息
Clin Transl Med. 2025 Mar;15(3):e70274. doi: 10.1002/ctm2.70274.
Abstract
摘要
Zotero 插件